The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc− cystine transporter: a new action for an old drug
Abstract
Although cyst(e)ine is nutritionally a non-essential amino acid, lymphoid cells cannot synthesize it, rendering their growth dependent on uptake of cyst(e)ine from their microenvironment. Accordingly, we previously suggested that the x(c)- plasma membrane cystine transporter provided a target for lymphoid cancer therapy. Its inhibition could lead to cyst(e)ine deficiency in lymphoma cells via reduction of both their cystine uptake and cysteine supply by somatic cells. In this study, using rat Nb2 lymphoma cultures, drugs were screened for growth arrest based on x(c)- inhibition. Sulfasalazine was fortuitously found to be a novel, potent inhibitor of the x(c)- transporter. It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c)--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid. Sulfasalazine was even more effective against human non-Hodgkin's lymphoma (DoHH2) cultures. In rats (n = 13), sulfasalazine (i.p.) markedly inhibited growth of well-developed, rapidly growing rat Nb2 lymphoma transplants without apparent side-effects. Reduced, macrophage-mediated supply of cysteine was probably involved. In five rats, 90-100% tumor growth suppression, relative to controls, was obtained. The x(c)- cystine transporter represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DLBCLs with low system xc− activity are more susceptible to ferroptosis”
From Ferroptosis: Death by Lipid Peroxidation (2016) · cites this paper as [77]
In the citing paper
“sulfasalazine potently inhibited the growth of lymphomas with low-level expression of SLC7A11, a subunit of system xc− [77, 78].”
From Ferroptosis: Death by Lipid Peroxidation (2016) · cites this paper as [77]
In the citing paper
“Since some leukemias and lymphomas have a defective transsulfuration pathway [76, 77]”
From Ferroptosis: Death by Lipid Peroxidation (2016) · cites this paper as [77]
Citations
Cites
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C. (1996) · JAMA · doi:10.1001/jama.1996.03540120077042 · Cited by 2,375
Determination of subcutaneous tumor size in athymic (nude) mice
Tomayko, M. M., & Reynolds, C. P. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00300234 · Cited by 1,830
Cancer: Principles and Practice of Oncology
Gunn, W. G. (1994) · JAMA · doi:10.1001/jama.1994.03510350091047 · Cited by 1,803
Inhibition of NF-κB by Sodium Salicylate and Aspirin
Kopp, E. B., & Ghosh, S. (1994) · Science · doi:10.1126/science.8052854 · Cited by 1,744
Sato, H., Tamba, M., Ishii, T., & Bannai, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11455 · Cited by 1,111
Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742
Wang, C.-Y., Guttridge, D. C., Mayo, M. W., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5923 · Cited by 594
Back, S. A., Gan, X., Li, Y., Rosenberg, P. A., & Volpe, J. J. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-16-06241.1998 · Cited by 586
Exchange of cystine and glutamate across plasma membrane of human fibroblasts.
Bannai, S. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35926-4 · Cited by 549
Analgesic-Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout
Insel, P. (1996) · Medical Entomology and Zoology · Cited by 416
Cited by
Sorted by citations
Items 201–300 of 644
Ferroptosis: Biochemistry and Biology in Cancers
Shi, Z., Zhang, L., Zheng, J., Sun, H., & Shao, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.579286 · Cited by 76
Grzes, K. M., Sanin, D. E., Kabat, A. M., Stanczak, M. A., Edwards-Hicks, J., Matsushita, M., Hackl, A., Hässler, F., Knoke, K., Zahalka, S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.009 · Cited by 70
YOSHIOKA, H., Kawamura, T., Muroi, M., Kondoh, Y., Honda, K., Kawatani, M., Aono, H., Waldmann, H., Watanabe, N., & Osada, H. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00028 · Cited by 72
Thanee, M., Loilome, W., Techasen, A., Sugihara, E., Okazaki, S., Abe, S., Ueda, S., Masuko, T., Namwat, N., Khuntikeo, N., et al. (2016) · Cancer Science · doi:10.1111/cas.12967 · Cited by 70
Antigen-presenting cells control T cell proliferation by regulating amino acid availability
Edinger, A. L., & Thompson, C. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042707999 · Cited by 69
Hu, X., Xu, Y. M., Xu, H., Jin, C., Zhang, H., Su, H., Li, Y., Zhou, K., & Ni, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.705786 · Cited by 67
Emerging Mechanisms and Targeted Therapy of Ferroptosis in Neurological Diseases and Neuro-oncology
Wang, Y., Tang, B., Zhu, J., Yu, J., Hui, J., Xia, S., & Ji, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72251 · Cited by 69
Ferroptosis-related small-molecule compounds in cancer therapy: Strategies and applications
Yin, L., Liu, P., Jin, Y., Ning, Z., Yang, Y., & Gao, H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114861 · Cited by 66
Targeting cell death in NAFLD: mechanisms and targeted therapies
Xu, H., Wan, S., An, Y., Wu, Q., Xing, Y.-H., Deng, C.-H., Zhang, P., Long, Y., Xu, B.-T., & Jiang, Z. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02168-z · Cited by 72
Ferroptosis as a new tool for tumor suppression through lipid peroxidation
Yang, X. P., Liu, Y., Wang, Z., Jin, Y., & Gu, W. J. (2024) · Communications Biology · doi:10.1038/s42003-024-07180-8 · Cited by 73
Kinoshita, H., OKABE, H., Beppu, T., Chikamoto, A., Hayashi, H., Imai, K., Mima, K., Nakagawa, S., Ishimoto, T., Miyake, K., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.2162 · Cited by 67
BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis
Schmitt, A. M., Grimm, M., Kreienkamp, N., Junge, H., Labisch, J., Schuhknecht, L., Schönfeld, C., Görsch, E., Tibello, A., Menck, K., et al. (2023) · Blood · doi:10.1182/blood.2022019274 · Cited by 67
Benlloch, M., Obrador, E., Vallés, S. L., Rodríguez, M. L., Sirerol, J. A., Alcácer, J., Pellicer, J. A., Palmer, R. S., Cerdá, C., Sáez, G. T., et al. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6437 · Cited by 68
Siska, P. J., Kim, B., Ji, X., Hoeksema, M. D., Massion, P. P., Beckermann, K. E., Wu, J., Chi, J., Hong, J., & Rathmell, J. C. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.08.013 · Cited by 63
Beatty, A., Fink, L. S., Singh, T., Strigun, A., Peter, E., Ferrer, C. M., Nicolas, É., Cai, K. Q., Moran, T. P., Reginato, M. J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0407 · Cited by 67
Ferroptosis is Involved in Hypoxic-ischemic Brain Damage in Neonatal Rats
Lin, W., Zhang, T., Zheng, J., Zhou, Y., Lin, Z., & Fu, X. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.02.013 · Cited by 64
Targeting antioxidant enzymes as a radiosensitizing strategy
Jiang, H., Wang, H., & Ridder, M. D. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.004 · Cited by 64
Bolli, E., O’Rourke, J. P., Conti, L., Lanzardo, S., Rolih, V., Christen, J. M., Barutello, G., Forni, M., Pericle, F., & Cavallo, F. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1408746 · Cited by 66
Targetting ferroptosis for blood cell-related diseases
Chen, Z., Jiang, J., Fu, N., & Chen, L. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1971237 · Cited by 65
Yuk, H., Abdullah, M., Kim, D.-H., Lee, H., & Lee, S. J. (2021) · Antioxidants · doi:10.3390/antiox10091347 · Cited by 65
Seib, T., Patel, S. A., & Bridges, R. J. (2011) · Glia · doi:10.1002/glia.21176 · Cited by 63
Ferroptosis as a new therapeutic opportunity for nonviral liver disease
Jia, M., Zhang, H., Qin, Q., Hou, Y., Zhang, X., Chen, D., Zhang, H., & Chen, Y. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174319 · Cited by 64
Nanodrug delivery systems for ferroptosis-based cancer therapy
Wang, Y., Sun, T., & Jiang, C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.034 · Cited by 66
Palazzo, I., Deistler, K., Hoang, T. V., Blackshaw, S., & Fischer, A. J. (2020) · Development · doi:10.1242/dev.183418 · Cited by 60
Research progress on SLC7A11 in the regulation of cystine/cysteine metabolism in tumors (Review)
Tang, X., Chen, W., Liu, H., Liu, N., Chen, D., Tian, D., & Wang, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.13165 · Cited by 59
Ferroptosis: The Silver Lining of Cancer Therapy
Tang, Z., Huang, Z., Huang, Y., Chen, Y., Huang, M., Liu, H., Ye, Q. A., Zhao, J., & Jia, B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.765859 · Cited by 62
Lin, C., Mabe, N. W., Lin, Y.-T., Yang, W., Tang, X., Hong, L. T., Sun, T., Force, J. M., Marks, J. R., Yao, T., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0499-y · Cited by 58
Antioxidant responses related to temozolomide resistance in glioblastoma
Campos-Sandoval, J. A., Gómez-García, M. C., Santos-Jiménez, J. D. L., Matés, J. M., Alonso, F. J., & Márquez, J. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105136 · Cited by 63
Ferroptosis: The Entanglement between Traditional Drugs and Nanodrugs in Tumor Therapy
Liu, K., Huang, L., Qi, S., Liu, S., Xie, W., Du, L., Jing, C., Zhang, X., Zhang, B., Liu, L., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203085 · Cited by 59
Miyoshi, S., Tsugawa, H., Matsuzaki, J., Hirata, K., Mori, H., Saya, H., Kanai∥, T., & Suzuki, H. (2018) · Anticancer Research · doi:10.21873/anticanres.12969 · Cited by 58
Oncology Therapeutics Targeting the Metabolism of Amino Acids
Muhammad, N., Lee, H. M., & Kim, J. (2020) · Cells · doi:10.3390/cells9081904 · Cited by 59
Dai, L., Cao, Y., Chen, Y., Parsons, C. H., & Qin, Z. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-30 · Cited by 57
Hagiwara, M., Kikuchi, E., Tanaka, N., Kosaka, T., Mikami, S., Saya, H., & Oya, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-3988-3 · Cited by 57
Ogihara, K., Kikuchi, E., Okazaki, S., Hagiwara, M., Takeda, T., Matsumoto, K., Kosaka, T., Mikami, S., Saya, H., & Oya, M. (2019) · Cancer Science · doi:10.1111/cas.13960 · Cited by 57
Sulfasalazine for brain cancer fits
Sontheimer, H. W., & Bridges, R. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.670634 · Cited by 56
Glutathione in metastases: From mechanisms to clinical applications
Estrela, J. M., Ortega, Á., Mena, S., Sirerol, J. A., & Obrador, E. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1136259 · Cited by 56
Antitumor Effect of 5-Aminolevulinic Acid Through Ferroptosis in Esophageal Squamous Cell Carcinoma
Shishido, Y., Amisaki, M., Matsumi, Y., Yakura, H., Nakayama, Y., Miyauchi, W., Miyatani, K., Matsunaga, T., Hanaki, T., Kihara, K., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09334-4 · Cited by 59
Role of ferroptosis in chronic kidney disease
Li, S., Han, Q., Liu, C., Wang, Y., Liu, F., Pan, S., Zuo, L., Gao, D., Chen, K., Feng, Q., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01422-8 · Cited by 66
Webster, J. M., Morton, C. A., Johnson, B. F., Yang, H., Rishel, M. J., Lee, B. D., Miao, Q., Chittari, P., Yapp, D. T. T., & Schaffer, P. C. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.126664 · Cited by 54
Shiozaki, A., Iitaka, D., Ichikawa, D., Nakashima, S., Fujiwara, H., Okamoto, K. K., Kubota, T., Komatsu, S., Kosuga, T., Takeshita, H., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0847-5 · Cited by 52
Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain
Fazzari, J., Lin, H., Murphy, C., Ungard, R. G., & Singh, G. (2015) · Scientific Reports · doi:10.1038/srep08380 · Cited by 52
Bernabucci, M., Notartomaso, S., Zappulla, C., Fazio, F., Cannella, M., Motolese, M., Battaglia, G., Bruno, V., Gradini, R., & Nicoletti, F. (2012) · Molecular Pain · doi:10.1186/1744-8069-8-77 · Cited by 52
Moujalled, D., Southon, A. G., Saleh, E., Brinkmann, K., Ke, F., Iliopoulos, M., Cross, R. S., Jenkins, M. R., Nhu, D., Wang, Z., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00977-2 · Cited by 52
Discovery and development of small molecule modulators targeting glutamine metabolism
Li, L., Meng, Y., Li, Z., Dai, W., Xu, X. J., Xiao-ling, B., & Bian, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.066 · Cited by 50
Immunometabolism: A new target for improving cancer immunotherapy
Guo, C., Chen, S., Liu, W., Ma, Y., Li, J., Fisher, P. B., Fang, X., & Wang, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.004 · Cited by 56
Solute carrier proteins and c-Myc: a strong connection in cancer progression
Panda, S., Banerjee, N., & Chatterjee, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.02.007 · Cited by 49
Molecular mechanisms of ferroptosis and their role in inflammation
Wang, F., He, J., Xing, R., Sha, T., & Sun, B. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.2016739 · Cited by 50
Ferroptosis: Mechanism and connections with cutaneous diseases
Liu, L., Lian, N., Shi, L., Hao, Z., & Chen, K. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1079548 · Cited by 52
Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury
Meyer, A. R., Engevik, A. C., Willet, S. G., Williams, J. A., Zou, Y., Massion, P. P., Mills, J. C., Choi, E.-Y. K., & Goldenring, J. R. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.015 · Cited by 49
Ma, Z., Zhang, H., Lian, M., Yue, C., Dong, G., Jin, Y., Li, R., Wan, H., Wang, R., Wang, Y., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5976 · Cited by 48
Hyperoxidation of ether-linked phospholipids accelerates neutrophil extracellular trap formation
Yotsumoto, S., Muroi, Y., Chiba, T., Ohmura, R., Yoneyama, M., Magarisawa, M., Dodo, K., Terayama, N., Sodeoka, M., Aoyagi, R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15668-z · Cited by 47
xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner
Miyamoto, Κ., Watanabe, M., Boku, S., Sukeno, M., Morita, M., Kondo, H., Sakaguchi, K., Taguchi, T., & Sakai, T. (2020) · Cancers · doi:10.3390/cancers12040827 · Cited by 50
Nagaraj, S., Rajaram, M. G., Arulmurugan, P., Baskaraboopathy, A., Karuppasamy, K., Jayappriyan, K. R., Sundararaj, R., & Rengasamy, R. (2012) · Biomedicine & Preventive Nutrition · doi:10.1016/j.bionut.2012.03.009 · Cited by 47
Xiong, Y., Yong, Z., Li, S., Wang, Q., Chen, X. '., Zhang, Z., Zhao, Q., Deng, Q., Yang, X., & Li, Z. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202310158 · Cited by 46
Application of natural products for inducing ferroptosis in tumor cells
Wu, Z., Zhong, M., Liu, Y., Xiong, Y., Gao, Z., Ma, J., Zhuang, G., & Hong, X. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2096 · Cited by 46
Inhibition of xc- transporter-mediated cystine uptake by sulfasalazine analogs
Shukla, K. H., Thomas, A. G., Ferraris, D. V., Hin, N., Sattler, R., Alt, J., Rojas, C. J., Slusher, B. S., & Tsukamoto, T. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.081 · Cited by 45
Jin, C., Zhang, P., Zhang, M., Zhang, X., Lv, L., Liu, H., Liu, Y., & Zhou, Y. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3009 · Cited by 44
Monitoring structural modulation of redox-sensitive proteins in cells with MS-CETSA
Sun, W., Dai, L., Yu, H., Puspita, B., Zhao, T., Li, F., Tan, J. L., Lim, Y. T., Chen, M. W., Sobota, R. M., et al. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101168 · Cited by 45
Novera, W., Lee, Z., Nin, D. S., Dai, M. Z.-Y., Idres, S. B., Wu, H., Damen, M. J. A., Tan, T. Z., Sim, A. Y. L., Long, Y. C., et al. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7850 · Cited by 44
Kwon, O.-S., Kwon, E.-J., Kong, H., Choi, J., Kim, Y. J., Lee, E., Kim, W., Lee, H., & Cha, H. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101719 · Cited by 44
CD44 polymorphisms and its variants, as an inconsistent marker in cancer investigations
Gomari, M. M., Farsimadan, M., Rostami, N., Mahmoudi, Z., Fadaie, M., Farhani, I., & Tarighi, P. (2021) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2021.108374 · Cited by 44
Yang, Y., Lin, Z., Han, Z., Wu, Z., Hua, J., Zhong, R. M., Zhao, R., Ran, H., Qu, K., Huang, H., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00659-x · Cited by 43
Molecular Hybridization as a Strategy for Developing Artemisinin-Derived Anticancer Candidates
Marchesi, E., Perrone, D., & Navacchia, M. L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092185 · Cited by 44
The Redox Paradox: Cancer’s Double-Edged Sword for Malignancy and Therapy
Ranbhise, J. S., Singh, M. K., Ju, S., Han, S., Yun, H. R., Kim, S. S., & Kang, I. (2025) · Antioxidants · doi:10.3390/antiox14101187 · Cited by 44
xCT modulation in gliomas: Relevance to energy metabolism and tumor microenvironment normalization
Savaskan, N. E., & Eyüpoglu, I. Y. (2010) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2010.07.003 · Cited by 41
Montesdeoca, N., Johannknecht, L., Efanova, E., Heinen‐Weiler, J., & Karges, J. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202412585 · Cited by 40
Vučetić, M., Daher, B., Cassim, S., Meira, W., & Pouysségur, J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02994-w · Cited by 40
Metabolite Transporters as Regulators of Immunity
Weiss, H. J., & Angiari, S. (2020) · Metabolites · doi:10.3390/metabo10100418 · Cited by 41
In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine
Gout, P. W., Simms, C. R., & Robertson, M. C. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200301000-00004 · Cited by 39
Self-citationMelatonin and ferroptosis: Mechanisms and therapeutic implications
Zhang, D., Jia, X., Lin, D., & Ma, J. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115909 · Cited by 39
Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Savaskan, N. E., Fan, Z., Broggini, T., Buchfelder, M., & Eyüpoglu, I. Y. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150122224158 · Cited by 38
Lin, J., Akiyama, M., Bica, I., Long, F. T., Henderson, C. F., Goddu, R. N., Suarez, V., Baker, B., Ida, T., Shinkai, Y., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00340 · Cited by 39
mTORC1 beyond anabolic metabolism: Regulation of cell death
Zhu, J., Wang, H., & Jiang, X. (2022) · The Journal of Cell Biology · doi:10.1083/jcb.202208103 · Cited by 42
Maier, J. P., Ravi, V. M., Kueckelhaus, J., Behringer, S. P., Garrelfs, N., Will, P., Sun, N., von Ehr, J., Goeldner, J. M., Pfeifer, D., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03937-9 · Cited by 39
Ferroptosis: A new insight for treatment of acute kidney injury
Li, S., Wang, R., Wang, Y., Liu, Y., Qiao, Y., Li, P., Chen, J., Pan, S., Feng, Q., Liu, Z., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1065867 · Cited by 40
Wang, Y., Zhang, L., Zhang, S., Liu, Z., & Chen, L. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b01511 · Cited by 37
Ferroptosis: Biology and Role in Gastrointestinal Disease
Escuder‐Rodríguez, J.-J., Liang, D., Jiang, X., & Sinicrope, F. A. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.051 · Cited by 41
Ferroptosis in Cancer and Inflammatory Diseases: Mechanisms and Therapeutic Implications
Shen, G., Liu, J., Wang, Y., Deng, Z., & Deng, F. (2025) · MedComm · doi:10.1002/mco2.70349 · Cited by 47
Pham, A., Blower, P. E., Alvarado, O., Ravula, R., Gout, P. W., & Huang, Y. S. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162248 · Cited by 37
Self-citationZhou, D., Lu, P., Mo, X., Yang, B., Chen, T., Yao, Y., Xiong, T., Lin, Y., & Yang, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1248934 · Cited by 38
Mastall, M., Roth, P., Bink, A., Maranta, A. F., Laubli, H. P., Hottinger, A. F., Hundsberger, T., Migliorini, D., Ochsenbein, A. F., Seystahl, K., et al. (2024) · BMC Cancer · doi:10.1186/s12885-023-11797-z · Cited by 40
Ashoub, M. H., Razavi, R., Heydaryan, K., Salavati‐Niasari, M., & Amiri, M. (2024) · European journal of medical research · doi:10.1186/s40001-024-01822-7 · Cited by 37
Liao, W., Zhang, R., Chen, G., Zhu, X., Wu, W., Chen, Z., Jiang, C., Lin, Z., Ma, L., & Yu, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116832 · Cited by 39
Ferroptosis in hematological malignancies and its potential network with abnormal tumor metabolism
Zhang, J., Liu, Y., Li, Q., Xu, A., Hu, Y., & Sun, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112747 · Cited by 36
Targeting the Macrophage-Ferroptosis Crosstalk: A Novel Insight into Tumor Immunotherapy
Zhou, Z., Xu, B., Hu, N., Guo, Z., Bao, W., Shao, B., & Yang, W. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2707203 · Cited by 37
Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer
Wang, Y., Sun, Y., Wang, F., Wang, H., & Hu, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115866 · Cited by 37
Amino Acid Metabolism Related to Immune Tolerance by MDSCs
Yang, B., Wang, X., & Ren, X. (2012) · International Reviews of Immunology · doi:10.3109/08830185.2012.679989 · Cited by 35
Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology
Fairweather, S. J., Shah, N., & Bröer, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_584 · Cited by 37
Werry, E. L., Liu, G. J., Lovelace, M. D., Nagarajah, R., Hickie, I. B., & Bennett, M. R. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.10.080 · Cited by 37
From mechanisms to medicine: Ferroptosis as a Therapeutic target in liver disorders
He, Y., Lin, Y., Song, J., Song, M., Nie, X., Sun, H. J., Xu, C., Han, Z., & Cai, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02121-2 · Cited by 36
Boutter, J., Huang, Y., Marovca, B., Vonderheit, A., Grotzer, M. A., Eckert, C., Cario, G., Wollscheid, B., Horváth, P., Bornhauser, B. C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2572 · Cited by 35
Zheng, Z., Luo, G., Shi, X., Long, Y., Shen, W., Li, Z., & Zhang, X. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00474-8 · Cited by 36
Ferroptosis-Driven Nanotherapeutics to Reverse Drug Resistance in Tumor Microenvironment
Zhu, L., Meng, D., Wang, X., & Chen, X. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00199 · Cited by 35
Seishima, R., Okabayashi, K., Nagano, O., Hasegawa, H., Tsuruta, M., Shimoda, M., Kameyama, K., Saya, H., & Kitagawa, Y. (2016) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.11.007 · Cited by 33
Merckx, E., Albertini, G., Paterka, M., Jensen, C., Albrecht, P., Dietrich, M., Liefferinge, J. V., Bentea, E., Verbruggen, L., Demuyser, T., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0787-0 · Cited by 33
The potential of ferroptosis combined with radiotherapy in cancer treatment
Lu, Z., Xiao, B., Chen, W., Tang, T., Zhuo, Q., & Chen, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1085581 · Cited by 35
Fan, F., Yang, C., Piao, E., Shi, J., & Zhang, J. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149733 · Cited by 37
A guide to ferroptosis in cancer
Yapici, F. I., Bebber, C. M., & von Karstedt, S. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13649 · Cited by 35
mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis
Li, C., Chen, H., Zhou, L., He, S., Chen, R., Wang, F., Liu, Z., Li, K., Cheng, L., Liu, Y., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0274-0 · Cited by 33
Is Ferroptosis a Future Direction in Exploring Cryptococcal Meningitis?
Xu, X., Lin, D., Tu, S., Gao, S., Shao, A., & Sheng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.598601 · Cited by 33
Metadata
- Authors
- Gout, P., Buckley, A., Simms, C., & Bruchovsky, N.
- Affiliations
- BC Cancer Agency (CA)
- University of Cincinnati Medical Center (US)
- Venue
- Leukemia
- Published
- 2001-10-01
- Volume
- 15
- Issue
- 10
- Pages
- 1633-1640
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2137749199
- Cited by
- 640
- References
- 41
- Citations by year
- 2026: 32 · 2025: 47 · 2024: 62 · 2023: 63 · 2022: 74 · 2021: 93 · 2020: 46 · 2019: 41 · 2018: 23 · 2017: 28 · 2016: 23 · 2015: 22 · 2014: 14 · 2013: 10 · 2012: 18
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ohio Cancer Research Associates
- National Institutes of Health (5r01dk053452-05)
- BC Cancer Agency
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 53452)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Sulfur Compounds in Biology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- sulfasalazine, cystine uptake, lymphoma, cysteine deficiency, non-Hodgkin lymphoma, sulfapyridine, 5-aminosalicylic acid, tumor growth inhibition, drug repurposing
- MeSH terms
- Animals, Anti-Inflammatory Agents, Non-Steroidal, Antineoplastic Agents, Carrier Proteins, Cell Division, Drug Evaluation, Preclinical, Humans, Injections, Intraperitoneal, Lymphoma, Neoplasm Transplantation, Rats, Inbred Strains, Sulfasalazine, Tumor Cells, Cultured, Inhibitory Concentration 50, Amino Acid Transport System y+, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
